Eagle Pharmaceuticals, Inc.
EGRX
EGRX was delisted on the 2nd of October, 2024.
174 hedge funds and large institutions have $832M invested in Eagle Pharmaceuticals, Inc. in 2018 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 55 increasing their positions, 62 reducing their positions, and 19 closing their positions.
26% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 19
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
11% more call options, than puts
Call options by funds: $7.07M | Put options by funds: $6.34M
2% more funds holding
Funds holding: 170 → 174 (+4)
2% less capital invested
Capital invested by funds: $853M → $832M (-$20.7M)
11% less repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 62
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$17.2M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
+$14.3M |
| 3 |
LSV Asset Management
Chicago,
Illinois
|
+$7.29M |
| 4 |
CEI
Clark Estates Inc
New York
|
+$3.27M |
| 5 |
GC
Guggenheim Capital
Chicago,
Illinois
|
+$3.17M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Prudential Financial
Newark,
New Jersey
|
-$12M |
| 2 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$9.76M |
| 3 |
First Eagle Investment Management
New York
|
-$5.85M |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
-$5.49M |
| 5 |
AL
AJO LP
Philadelphia,
Pennsylvania
|
-$3.4M |
EGRX Hedge Fund Activity: Q1 2018 in Review
174 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Eagle Pharmaceuticals, Inc. (EGRX) for Q1 2018, worth a combined $832M — down 2.4% from $853M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new EGRX positions and 19 closed out — a net gain of 5 holders — while 55 added to existing stakes and 62 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $17.2M. The largest seller was Prudential Financial, cutting an estimated $12M.
- 174 institutional investors held Eagle Pharmaceuticals, Inc. (EGRX) as of Q1 2018, up from 170 in Q4 2017.
- Funds reported $832M of Eagle Pharmaceuticals, Inc. stock for Q1 2018, down 2.4% quarter-over-quarter.
- 24 funds opened new Eagle Pharmaceuticals, Inc. positions in Q1 2018 and 19 closed out, a net change of +5 holders.
- The largest Eagle Pharmaceuticals, Inc. buyer in Q1 2018 was Citadel Advisors, an estimated $17.2M added.
- The largest Eagle Pharmaceuticals, Inc. seller in Q1 2018 was Prudential Financial, an estimated $12M sold.
Based on aggregated 13F filings for Q1 2018.